Medtronic plc, a leader in healthcare technology, has announced a significant regulatory milestone for its Hugo™ robotic-assisted surgery $(RAS.AU)$ system. The company has secured the CE Mark for its LigaSure™ RAS vessel-sealing technology, enhancing the capabilities of the Hugo™ RAS system for gynecologic, general, and urologic procedures in Europe. This development marks the integration of Medtronic's trusted vessel-sealing technology onto the Hugo™ system, which has been utilized in over 35 million procedures globally. Additionally, in the U.S., the Hugo™ RAS system is under an ongoing regulatory review by the Food and Drug Administration for a urology indication, with potential market entry anticipated later this fiscal year. The system is currently in use across 30+ countries, further solidifying its growing momentum in the surgical field.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.